Switzer TV

 

In our last episode of 2025, we get the heavy hitters. This week on Switzer Investing TV, Peter Switzer sits down with three seasoned market pros to cut through the noise and talk straight about where the real growth opportunities may lie heading into 2026.

With tech stocks sold off, resources rotating back into favour, and AI fears dominating headlines, each guest lays out what they’d actually buy now and why.

Adam Dawes kicks things off by explaining why selective commodities, developers and beaten-up growth names are back on the radar, and where investors need to be careful.

Jun Bei Liu then shares her “buy low” Christmas gift ideas, focusing on high-quality growth companies that have fallen out of favour but continue to grow earnings. Finally, Paul Rickard wraps up the year with a pragmatic take on oversold tech, patience, and which names could reward investors willing to look past short-term fear.

Interview timecodes:

00:01:01 - Adam Dawes, Shaw and Partners

00:17:41 - Jun Bei Liu, TenCap

00:25:37 - Paul Rickard, Switzer Report

 

This is our last show for 2025. We thank you for joining us and we'll see you on 10 January, 2026 with a new year of Switzer Investing TV.

Switzer Investing TV (15/12/25): What would our experts invest in now for growth in 2026?

In our last episode of 2025, we get the heavy hitters. This week on Switzer Investing TV, Peter Switzer sits down with three seasoned market pros to cut through the noise and talk straight about where the real growth opportunities may lie heading into 2026.

More videos

Did health authorities make the right decision about COVID-19?

Dr Ross Walker shares his criticisms about how the coronavirus pandemic has been handled.

Series: ,
Time for Gladys to mask up!

Peter Switzer and Paul Rickard discuss masking up for the economy, rising gold prices and the looming reporting season.

Series: ,
Experts give these tech stocks a thumbs up!

On this week's show: Burman Invest's Julia Lee, Medallion's Michael Wayne, Morgans' Michael Knox and Switzer's Paul Rickard.

Series: ,
What therapies are available for COVID-19?

Dr Ross Walker examines the effectiveness of hydroxychloroquine.

Series: ,
Why is the stock market ignoring infections?

Peter Switzer and Paul Rickard discuss gains in the stock market despite infection rates in Victoria and the US, the Aussie dollar moving above 71 US cents and when employees will head back to the office.

Series: ,
Could Afterpay really go to $100? Plus, reliable stocks you can trust!

Joining Peter Switzer on this week's show: Burman Invest's Julia Lee, Shaw and Partners' Adam Dawes, FNArena's Rudi Filapek-Vandyck and Metrics Credit Partners' Andrew Lockhart.

Series: ,
The COVID-19 game-changer

With over 100 vaccines for COVID-19 currently being trialled, Dr Ross Walker explains what vaccination is and how the latest research into Coronavirus vaccines is progressing.

Series: ,
Steven Turner from Rafaella Resources (ASX:RFR)

Peter Switzer is joined by the Managing Director of Rafaella Resources (RFR), Steven Turner.

Series: ,
Super is in shambles!

Peter Switzer and Paul Rickard discuss problems with the compulsory superannuation system, Wall Street madness overnight, the COVID-19 situation in Victoria and what the iron ore price says about the economy.

Series: ,
Switzer does drugs! Coronavirus killers, medicinal cannabis & other drugs!

Julia Lee, James Graham, Rhys Cohen and Paul Rickard join this week's show to discuss investing in the drug space.

Series: ,
Why are there more COVID-19 cases in the northern hemisphere?

Dr Ross Walker explains what kind of people and places are more susceptible to the Coronavirus.

Series: ,
Are Afterpay's founders exiting and should you follow?

Peter Switzer and Paul Rickard discuss the latest news on Afterpay, Victorian Premier Daniel Andrew's handling of COVID-19 and why US share players are ignoring a spike in cases.

Series: ,
1 42 43 44 45 46 51

Fill in the form below to subscribe to Switzer Daily and get our latest articles, videos and podcasts sent straight to your inbox

Get the latest financial, business, and political expert commentary delivered to your inbox.

When you sign up, we will never give away or sell or barter or trade your email address.

And you can unsubscribe at any time!
Subscribe
© 2006-2021 Switzer. All Rights Reserved. Australian Financial Services Licence Number 286531. 
shopping-cartphoneenvelopedollargraduation-cap linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram